Brief: Nanoviricides Inc - On March 27, Co Entered Into License Agreement With Karveer Meditech Private Limited

NanoViricides,

31/03/2023 22:33

March 31 (Reuters) - NanoViricides Inc  NNVC.A :
    * NANOVIRICIDES INC - ON MARCH 27, CO ENTERED INTO A LICENSE
AGREEMENT WITH KARVEER MEDITECH PRIVATE LIMITED
    * NANOVIRICIDES- GRANTED KARVEER A LIMITED,
NON-TRANSFERABLE,
EXCLUSIVE LICENSE FOR  DEVELOPMENT AND COMMERCIALIZATION
NV-COV-2 AND NV-COV-2-R IN INDIA
    * NANOVIRICIDES- GRANTED KARVEER A LIMITED,
NON-TRANSFERABLE,
EXCLUSIVE LICENSE FOR FURTHER USE, SALE, OR OFFER OF SALE
NV-COV-2 AND NV-COV-2-R IN INDIA
    * NANOVIRICIDES- KARVEER AGREED TO SPONSOR THE CLINICAL TEST
DRUG
CANDIDATES FOR PHASE I AND PHASE II CLINICAL TRIALS
    * NANOVIRICIDES- PURSUANT TO DEAL, CO TO REIMBURSE KARVEER
FOR
DIRECT & INDIRECT COSTS INCURRED FOR TRIALS & CUSTOMARY FEE OF
30% OF SUCH COSTS
    * NANOVIRICIDES- KARVEER SHALL PAY CO 70% OF INVOICED
COMMERCIAL
SALES OF EITHER OR BOTH CLINICAL TEST DRUG CANDIDATES TO
UNAFFILIATED THIRD PARTIES
    * NANOVIRICIDES- CO SHALL HAVE THE RIGHTS TO THE DATA
GENERATED BY
KARVEER IN THE CLINICAL TRIALS FOR USE IN OTHER JURISDICTIONS
    * NANOVIRICIDES- KARVEER SHALL PROVIDE THE COMPANY WITH
APPLICABLE
REPORTS AND DATA


Further company coverage:  NNVC.A 

 ((Reuters.Briefs@thomsonreuters.com;))